GlassScriptPhysician profile
Gary Grayson Lehman
NPI 1912969833
$3,845.56
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $726 · 2021: $958 · 2022: $797 · 2023: $259 · 2024: $51.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $460.05 | 2019-2023 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $443.56 | 2019-2022 | |
| Lilly USA, LLC | $322.74 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $257.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $247.91 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $207.84 | 2019-2022 | |
| Novo Nordisk INC | $197.21 | 2019-2021 | |
| Amgen INC. | $187.29 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $155.71 | 2019-2023 | |
| Esperion Therapeutics, INC. | $110.07 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $81.40 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $78.86 | 2022-2023 | Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $76.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.71 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $62.31 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.